Immunomic Therapeutics, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Immunomic Therapeutics, Inc. – Product Pipeline Review – 2016’, provides an overview of the Immunomic Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc.

The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Immunomic Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Immunomic Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Immunomic Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immunomic Therapeutics, Inc. Snapshot 5

Immunomic Therapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Immunomic Therapeutics, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Immunomic Therapeutics, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Combination Treatment Modalities 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Immunomic Therapeutics, Inc. - Pipeline Products Glance 14

Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Immunomic Therapeutics, Inc. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Immunomic Therapeutics, Inc. - Drug Profiles 18

TriMix-DC 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ASP-4070 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Cellular Immunotherapy for HIV 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MC-LAMP-Vax 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

pp65 DC + Td 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ARA-LAMP-Vax 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

HIV-LAMP-Vax 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

TN-LAMP-vax 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Antigen mRNA Vaccine + LAMP 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

JCC-LAMP-Vax 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Multi-LAMP-Vax 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Immunomic Therapeutics, Inc. - Pipeline Analysis 34

Immunomic Therapeutics, Inc. - Pipeline Products by Target 34

Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration 35

Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type 36

Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37

Immunomic Therapeutics, Inc. - Recent Pipeline Updates 38

Immunomic Therapeutics, Inc. - Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Immunomic Therapeutics, Inc., Key Information 5

Immunomic Therapeutics, Inc., Key Facts 5

Immunomic Therapeutics, Inc. – Pipeline by Indication, 2016 8

Immunomic Therapeutics, Inc. – Pipeline by Stage of Development, 2016 9

Immunomic Therapeutics, Inc. – Monotherapy Products in Pipeline, 2016 10

Immunomic Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2016 11

Immunomic Therapeutics, Inc. – Out-Licensed Products in Pipeline, 2016 12

Immunomic Therapeutics, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Immunomic Therapeutics, Inc. – Phase II, 2016 14

Immunomic Therapeutics, Inc. – Phase I, 2016 15

Immunomic Therapeutics, Inc. – Preclinical, 2016 16

Immunomic Therapeutics, Inc. – Discovery, 2016 17

Immunomic Therapeutics, Inc. – Pipeline by Target, 2016 34

Immunomic Therapeutics, Inc. – Pipeline by Route of Administration, 2016 35

Immunomic Therapeutics, Inc. – Pipeline by Molecule Type, 2016 36

Immunomic Therapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 37

Immunomic Therapeutics, Inc. – Recent Pipeline Updates, 2016 38

Immunomic Therapeutics, Inc., Other Locations 40

List of Figures

List of Figures

Immunomic Therapeutics, Inc. – Pipeline by Top 10 Indication, 2016 7

Immunomic Therapeutics, Inc. – Pipeline by Stage of Development, 2016 9

Immunomic Therapeutics, Inc. – Monotherapy Products in Pipeline, 2016 10

Immunomic Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2016 11

Immunomic Therapeutics, Inc. – Out-Licensed Products in Pipeline, 2016 12

Immunomic Therapeutics, Inc. – Pipeline by Top 10 Target, 2016 34

Immunomic Therapeutics, Inc. – Pipeline by Route of Administration, 2016 35

Immunomic Therapeutics, Inc. – Pipeline by Molecule Type, 2016 36

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports